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INTRODUCTION
People with posttraumatic stress disorder (PTSD), experience an excess mortality rate two to three times higher than the general population [1] [2] [3] . Previous research has demonstrated that PTSD is associated with poor physical health [4] , including the presence and severity of cardiovascular diseases (CVD), which predicts mortality independent of age, gender, and conventional risk factors [5] . To assist clinicians in identifying and treating patients at an increased risk of CVD, the concept of the metabolic syndrome (MetS) has been introduced. MetS is defined by a constellation of risk factors including central obesity, high blood pressure, low high-density lipoprotein (HDL) cholesterol, elevated triglycerides and hyperglycemia. In the general population, these clustered risk factors have been associated with the development of CVD and excess mortality [6] [7] [8] . Although several definitions have been proposed for MetS, the most commonly used are the Adult Treatment Panel III (ATP-III) and adapted ATP-III criteria (ATP-III-A) [9, 10] by the National Cholesterol Education Program (NCEP) and the International Diabetes Federation criteria (IDF) [11] by the World Health Organization (WHO) [12] . Current definitions for MetS are aimed at being easy to use in clinical settings and share similar diagnostic thresholds. However, the role of abdominal obesity is central to the IDF definition [11] , with provision of ethnic specific thresholds for waist circumference, while central obesity is not a mandatory NCEP/ATP [9, 10] MetS criterion. As a prevalent condition and predictor of CVD across racial, gender, and age groups, MetS provides the opportunity to identify high-risk populations and prevent the progression of some major causes of morbidity and mortality [13] .
Despite the established link between the MetS and mental disorders such as schizophrenia [14] [15] [16] , depression [17] and bipolar disorder [18] , little research
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appears to have considered the prevalence of MetS and its components among people with PTSD. Specifically, one previous meta-analysis [19] 
METHODS

Inclusion and Exclusion Criteria
This systematic review was conducted in accordance with the MOOSE guidelines [20] and in line with the Preferred Reporting Items for Systematic Reviews and Meta- insufficient data for extraction of MetS frequencies, and (c) restriction to children and/or adolescents. In the case of multiple publications from the same study, only the most relevant paper or article was included. When required, we contacted the primary/corresponding authors of potential studies to (a) confirm eligibility, and (b)
acquire the variables of interest if they were not available in the publication. Authors of articles were contacted up to two times over a 3-week period.
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Search Criteria, Study Selection and Critical Appraisal
Two independent authors (SR, DV) searched Medline, PsycARTICLES, Embase and CINAHL from database inception to February 1 st , 2015. Key words used were "metabolic syndrome" AND "posttraumatic stress disorder" in the title, abstract or index term fields. Manual searches were also conducted using the reference lists from recovered articles and the meta-analysis of Bartoli et al. [19] . After the removal of duplicates, both reviewers screened the titles and abstracts of all potentially eligible articles. Both authors applied the eligibility criteria, and a list of full text articles was developed through consensus. The two reviewers then considered the full texts of these articles and the final list of included articles was reached through consensus. A third reviewer (BS) was available for mediation throughout this process.
Methodological appraisal was performed according to PRISMA standards [21] , including evaluation of bias (confounding, overlapping data, publication bias).
Publication bias was tested using the Egger's regression method [24] and BeggMazumdar test [25] , with a p-value <0.05 suggesting the presence of bias. In addition, a funnel plot was created, in which the study-specific effect estimates are displayed in relation to the standard error in order to assess the potential presence of publication bias.
Statistical Analyses
We pooled individual study data using DerSimonian-Laird proportion method [26] with StatsDirect. Due to anticipated heterogeneity, a random effects meta-analysis was employed. We calculated the relative risk (RR) of MetS and its components between people with PTSD and matched general population control groups, also only
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using data from studies in which they were directly compared. We conducted several meta-regression analyses (if N≥3) to investigate potential moderators (age, percentage males, major depression disorder comorbidity prevalence, prevalence of those receiving antipsychotic treatment, smoking prevalence, hostile personality or not)
with Comprehensive Meta Analysis (version 3).
RESULTS
Search Results and Included Participants
Our search yielded 752 publications of which nine [27] [28] [29] [30] [31] [32] [33] [34] [35] [Insert Figure 1 about here]
Prevalence of Metabolic Syndrome among people with PTSD
It was possible to pool data from 9 unique studies which established the estimated 
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Individual Metabolic Abnormalities among people with PTSD
Three studies [28, 32, 35] reported on obesity frequency defined as waist circumference (>102cm in males and >88cm in females (ATP-III or ATP-III-A), while none of the studies reported the obesity frequency following the ethnicityspecific IDF-criteria. Overall, the proportion of people with PTSD with abdominal obesity by the ATP definitions was 49.3% (n=194; 95%CI=29.7%-69.0%; Q=14.8, p<0.001). It was possible to pool data from 3 studies studies [28, 32, 35] 
Subgroup analyses and Predictors of Metabolic Syndrome
The pooled MetS prevalence in Europe (Bosnia-Herzegovina) was 39.6% (N=3; 
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Relative Risk (RR) of MetS and Metabolic Abnormalities in Persons with
PTSD Compared with Age-And Gender Matched General Population Controls
Four studies [27, 28, 30, 34] (Figure 2 ).
[Insert Figure 2 about here]
DISCUSSION
In total, 38.7% (95% CI=32.1%-45.6%) of the included PTSD population had MetS and the relative risk for MetS was almost two times higher than in age-and gender matched general population controls (RR=1.82; 95%CI=1.72-1.92; p<0.001). The high prevalence of MetS and its constituent risk factors established within the current meta-analysis are of considerable concern.
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Knowledge of factors associated with the highest MetS risk can help to identify individuals with PTSD at greatest need for intensive monitoring and intervention. Consistent with population studies [36, 37] , we encountered no significant differences as a function of the number of women included within the studies possibly suggesting that men and women with PTSD require the same care.
However, our findings should be interpreted with some caution due to the fact women were underrepresented across the 9 included studies (11%) and the studies reviewed did not report disaggregated MetS data by gender precluding direct comparison. In our exploratory meta-regression, we were not able to elucidate any significant moderators. This is almost certainly due to the paucity of data and the current metaregression analyses should be viewed as exploratory. The fact that age differences between studies was not associated with MetS prevalence may be due to the limited mean age variation across the included studies (range=44-61 years). We did not find a difference between different populations (e.g., veterans or not) however this should be interpreted with caution as the majority of the included studies recruited participants from a veteran background (N=6). Previous research [17] demonstrated that people with MDD are at an increased risk for MetS. At study level the variability in
percentage of people with PTSD with co-morbid MDD did not appear to explain the variability in MetS prevalence. Findings of individual studies were also inconsistent.
While Jakovljević et al. [33] showed that PTSD among war veterans with MDD have a higher MetS risk than those without MDD, Weiss et al. [29] and Heppner et al. [31] indicated that MetS risk was not different for participants with comorbid PTSD and depression than for those with PTSD alone. The strongest evidence to date that the association of PTSD to incident cardio-metabolic diseases is independent of general distress is a recent study by Vaccarino et al. [38] in which it was found that adjustment for depression and other psychiatric diagnoses did not diminish the PTSD -cardiometabolic disease association. Future studies that focus on the unique association of PTSD with cardiometabolic disease risk mechanisms are however needed before any firm conclusions can be made.
Future Research
The current meta-analysis provides some indications for future research. First, since antipsychotic medications are increasingly used as off-label treatments for PTSD [39] and as an adjunctive treatment for co-morbid MDD [40] , research on the underlying mechanisms for the development of metabolic abnormalities after pharmacotherapy initiation is needed. Future studies should examine as well more in detail whether antidepressants or mood stabilizers significantly modulate MetS risk. For example, previous studies [41, 42] found that some antidepressants may, in some circumstances, reduce hyperglycemia, normalize glucose homeostasis and also increase insulin sensitivity, whereas others, including tricyclic antidepressants, may exacerbate glycemic dysfunction or have little effect on glucose homeostasis [43, 44] .
Second, the pathophysiology underlying the association between PTSD and MetS is
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complex and not well understood, requiring further investigation [45] . Emerging evidence suggests that both share pathophysiological features, including hypothalamic-pituitary-adrenal (HPA) and sympathoadrenomedullary dysfunction [46, 47] , inflammation [48] , common genetic links and epigenetic interactions [49, 50] . Third the extent to which traumatic experiences associated with physical injury may moderate associations between PTSD and MetS need to be examined, particularly in relation to compromised function of the endocrine organs.
Additionally, traumatic experience co-incident with central nervous system damage responsible for impulse control and daily life functioning, such as might occur in traumatic brain injury, may have adverse effects on the development of MetS through poor lifestyle. However, psychiatric comorbidity may also have a pivotal role and requires careful consideration. Fourth, it might be that a cumulative long-term effect of poor health behaviors places people with PTSD at the greatest risk for cardiometabolic disorders, more so than the psychiatric diagnosis per se. People with PTSD are more likely than the general population to have unhealthy lifestyle behaviors, such as being sedentary [51] , smoking [52] , alcohol and substance abuse [53] , and having diets that are high in saturated fats and refined sugars [54] , while low in fruit [55] , placing them at higher risk for MetS and CVD than the general population. Future research should comprehensively assess MetS risk factors and evaluate lifestyle interventions. Previous research [56] demonstrated that a 12-week exercise programme in addition to usual care reduces PTSD and depressive symptoms, while decreasing waist circumference, improving sleep quality, and reducing sedentary time. Finally, long-term follow-up is required to accurately document the emergence of more distal outcomes, such as diabetes, ischemic heart disease, medical costs, and premature mortality.
Limitations
Whilst the current meta-analysis is a first to investigate the prevalence of MetS and its constituents in people with PTSD conducted to date, we should acknowledge that variables such as psychotropic medication use, trauma exposure, time since exposure and diagnosis, personality factors (e.g. level of hostility) and lifestyle habits were not reported or were insufficiently reported or controlled for in most available studies. In addition, the low number of studies that have documented MetS within PTSD samples to date resulted in limited numbers of participants and studies available for review.
Nevertheless allowing for these caveats, the results of the current study provide a unique insight in the MetS risk among people with PTSD. Given the predictive accuracy of MetS for mortality and that CVD appears to contribute to a significant amount of the excess premature mortality among people with PTSD, the results of the present study are of clinical relevance and concern.
Conclusions
The current meta-analysis demonstrates that Metabolic Syndrome and its constituent components are highly prevalent amongst individuals identified with PTSD, who are almost twice as likely to have MetS compared to age and sex matched controls. The findings underscore the need for a multidisciplinary approach to assessment for patients presenting with PTSD that includes a focus on physical health as well as psychiatric symptoms. Treatment facilities should provide lifestyle interventions.
Future research should focus on how cardio-metabolic outcomes are moderated by clinical and treatment characteristics and genetic factors. 
